Table 1.
Patients' characteristics
| N = 232 | |
|---|---|
| Age (years, median, range) | 50, 18–73 |
| Sex (M/F) | 135 (58.19%)/97 (41.81%) |
| Type of donor | |
| MSD | 107 (46.12%) |
| MUD | 54 (23.28%) |
| Haploidentical | 53 (22.84%) |
| MMSD | 17 (7.33%) |
| Diagnosis | |
| AML | 92 (39.66%) |
| ALL | 29 (14.50%) |
| MDS | 25 (12.50%) |
| NHL | 18 (9%) |
| MPN | 17 (8.50%) |
| HL | 10 (5%) |
| PCM | 8 (4%) |
| Other | 33 (16.50%) |
| Conditioning | |
| RIC/MAC/NMA | 104 (44.83%)/125 (53.88%)/3 (1.29%) |
| Post-transplant complications | |
| aGvHD (I–IV) | 91 (39.22%) |
| aGvHD (II–IV) | 48 (20.69%) |
| cGvHD | 46 (19.83%) |
| cGvHD de novo/progression of aGvHD to cGvHD/after aGvHD remission | 17 (36.96%)/8 (17.39%)/20 (43.48%) |
| CMV | 90 (38.79%) |
| Relapse | 31 (13.36%) |
| Death | 30 (12.93%) |
| No complicationsa | 83 (35.78%) |
aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD; graft-versus-host disease; MMSD, mismatched sibling donor; MPN, myeloproliferative neoplasm; MSD, matched sibling donor; MUD, matched unrelated donor; PCM, plasma cell myeloma; RIC, reduced intensity conditioning; MAC, myeloablative conditioning.
Fig 1.
MICB genetic variants and development of cGvHD. (a) Donor rs1065056 G allele was less common among patients who developed cGvHD. (b) Donor rs3828903 G allele was more prevalent among recipients lacking cGvHD post-transplantation. cGvHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.
Fig 2.
Associations between the MICB genotype and the risk of CMV infection development. (a) CMV infection was less frequent in recipients carrying the rs1065075 G allele. (b) Lower incidence of CMV infection in patients transplanted from donors with rs1065075 G allele. CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation.
Table 2.
Results of the multivariate analysis for CMV risk factors
| Variables | P value | OR | 95% CI |
|---|---|---|---|
| Age | 0.5988 | 0.9937 | 0.9702–1.0176 |
| D/R HLA compatibility | 0.0142 | 0.4276 | 0.2144–0.8385 |
| Recipient CMV IgG status | <0.0001 | 16.2592 | 4.8663–76.9165 |
| Donor CMV IgG status | 0.1884 | 0.5834 | 0.2570–1.2944 |
| Donor sex | 0.1606 | 1.6562 | 0.8250–3.3949 |
| MICB rs1065057 G allele | 0.0238 | 0.4701 | 0.2417–0.8988 |
Table 3.
Serum sMICB concentrations in HSCT recipients
| No CMV (pg/mL) | CMV [pg/mL] | No cGvHD (pg/mL) | cGvHD (pg/mL) | |
|---|---|---|---|---|
| Mean | 67.13 | 96.85 | 62.47 | 116.2 |
| SD | 54.23 | 72.04 | 49.88 | 77.03 |
| Std. Error | 8.47 | 12.18 | 6.73 | 15.72 |
| 25–75% percentile | 25.38–94.86 | 39.42–129.8 | 26.53–88.25 | 71.60–145.2 |
| 95% CI | 50.01–84.25 | 72.10–121.6 | 48.98–75.95 | 83.69–148.7 |
Fig 3.
Serum sMICB levels in recipients diagnosed with various post-transplant complications. (a) Increased sMICB concentration in recipients with CMV infection. (b) Higher sMICB level in patients who developed chronic form of GvHD. cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD, graft-versus-host-disease; sMICB, soluble MICB.
Table 4.
Mean serum sMICB concentrations of patients with various MICB genotypes
| MICB SNP | ||
|---|---|---|
| Variant | rs1065057 | rs3828903 |
| AA | 91.47 pg/mL | 90.45 pg/mL |
| AG | 74.95 pg/mL | 90.48 pg/mL |
| GG | 39.78 pg/mL | 63.49 pg/mL |
Fig 4.
Relationships between serum sMICB and two MICB SNPs. (a) Lower sMICB level in serum samples of MICB rs1065057 GG homozygous patients. (b) Differences in sMICB concentration between recipients carrying various MICB rs3828903 genotypes. sMICB, soluble MICB; SNPs, single nucleotide polymorphism.